# US 2026/0098263 A1 · Modified double-stranded rna agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098263 A1
- Document ID: US20260098263A1
- Status: Published application
- Kind: A1
- Application number: 19/079,175
- Filed: 2025-03-13
- Published: 2026-04-09
- Earliest claimed: 2014-08-20
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Martin MAIER; Don FOSTER; Stuart MILSTEIN; Satya KUCHIMANCHI; Vasant JADHAV; Kallanthottathil RAJEEV; Muthiah MANOHARAN; Rubina PARMAR
- Web page: https://patentgrep.com/patent/US20260098263A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/313: Phosphorodithioates
- C12N 2310/32: of the sugar
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N 2310/332: Abasic residue
- C12N 2310/335: Modified T or U
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N 2310/533: having a mismatch or nick in at least one of the strands
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N 2320/52: modulating the physical stability, e.g. GC-content
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The sense strand of the dsRNA agent comprises at least one thermally destabilizing nucleotide, and at least one said thermally destabilizing nucleotide occurring at a site opposite to the seed region (positions 2-8) of the antisense strand; and the antisense strand of the dsRNA agent comprises. at least two modified nucleotides that provide the nucleotide a steric bulk that is less than or equal to the steric bulk of a 2′—OMe modification, wherein said modified nucleotides are separated by 11 nucleotides in length. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.

## Claims

### Claim 1

A double-stranded RNA (dsRNA) comprising a sense strand having 21 nucleotides and an antisense strand having 21-23 nucleotides that is at least 85% complementary to a portion of a target mRNA of a target gene, wherein:
(a) each nucleotide of the sense and antisense strands has a modification independently selected from the group consisting of 2′-O-Methyl (2′-OMe) and 2′-deoxy-2′-fluoro (2′-F);
(b) the sense strand comprises 2′-F modifications only at positions 7, 9, 10, and 11, counting from the 5′-end of the sense strand;
(c) the antisense strand comprises 2′-F modifications only at positions 2, 6, 9, 14, and 16, counting from the 5′-end of the antisense strand;
(d) the sense and antisense strands form a duplex region that is 21 base pairs in length;
(e) the dsRNA is optionally covalently conjugated to one or more ligands;
(f) the dsRNA has a blunt end at the 5′-end of the antisense strand; and
(g) phosphorothioate internucleotide linkage modifications, when present, only occur within a terminal region at one or both termini of the sense strand, one or both termini of the antisense strand, or one or both termini of both strands, wherein the terminal region is the last 5 nucleotides of a strand.

### Claim 2 (depends on 1)

The dsRNA of claim 1, wherein position 1 of the antisense strand, counting from the 5′-end of the antisense strand, contains a 2′-OMe modification.

### Claim 3 (depends on 1)

The dsRNA of claim 1, wherein at least one ligand is an asialoglycoprotein receptor (ASGPR) ligand, and wherein the ASGPR ligand is attached to the 5′-end or 3′-end of the sense strand.

### Claim 4 (depends on 3)

The dsRNA of claim 3, wherein the ASGPR ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

### Claim 5 (depends on 3)

The dsRNA of claim 3, wherein the ASGPR ligand is:

### Claim 6 (depends on 1)

The dsRNA of claim 1, wherein the first base pair within the duplex region from the 5′-end of the antisense strand is an A:U base pair.

### Claim 7 (depends on 1)

The dsRNA of claim 1, comprising a 5′-phosphate or a 5′-phosphate modification at the 5′-end of the antisense strand.

### Claim 8 (depends on 7)

The dsRNA of claim 7, comprising a 5′-vinyl phosphonate at the 5′-end of the antisense strand.

### Claim 9 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand contains 23 nucleotides.

### Claim 10 (depends on 1)

The dsRNA of claim 1, wherein both ends of the dsRNA are blunt ends.

### Claim 11 (depends on 1)

The dsRNA of claim 1, having at least 2 nucleotides linked through a phosphorothioate internucleotide linkage at one end or at each end of the sense strand, the antisense strand, or both strands.

### Claim 12 (depends on 11)

The dsRNA of claim 11, having 3 nucleotides linked through phosphorothioate internucleotide linkages at one end or at each end of the antisense strand.

### Claim 13 (depends on 12)

The dsRNA of claim 12, having 3 nucleotides linked through phosphorothioate internucleotide linkages at each end of the antisense strand.

### Claim 14 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand comprises only two blocks of two phosphorothioate internucleotide linkages separated by 18 phosphate internucleotide linkages.

### Claim 15 (depends on 11)

The dsRNA of claim 11, wherein the sense strand comprises only one block of two phosphorothioate internucleotide linkages.

### Claim 16 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand is at least 90% complementary to a portion of the target mRNA.

### Claim 17 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand is at least 95% complementary to a portion of the target mRNA.

### Claim 18 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand contains an overhang region consisting of 2 nucleotides in length at the 3′-end of the antisense strand; and wherein the antisense strand contains one or more mismatches to the target mRNA occurring at the overhang region.

### Claim 19 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand contains one or more mismatches to the target mRNA occurring at one or more of the following nucleotides: the first 5 nucleotides from the 5′-end of the antisense strand, and the first 5 nucleotides from the 3′-end of the antisense strand.

### Claim 20 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand contains one or more mismatches to the target mRNA occurring at only one or more of the following nucleotides: first nucleotide from the 5′-end of the antisense strand, and the first 5 nucleotides from the 3′-end of the antisense strand.

### Claim 21

A double-stranded RNA (dsRNA) comprising a sense strand having 21 nucleotides and an antisense strand having 23 nucleotides that is at least 95% complementary to a portion of a target mRNA of a target gene, wherein:
(a) each nucleotide of the sense and antisense strands has a modification independently selected from the group consisting of 2′-O-Methyl (2′-OMe) and 2′-deoxy-2′-fluoro (2′-F);
(b) the sense strand comprises 2′-F modifications only at positions 7, 9, 10, and 11, counting from the 5′-end of the sense strand;
(c) the antisense strand comprises 2′-F modifications only at positions 2, 6, 9, 14, and 16, counting from the 5′-end of the antisense strand;
(d) the sense and antisense strands form a duplex region that is 21 base pairs in length;
(e) the dsRNA is covalently conjugated to a ligand at the 3′-end of the sense strand;
(f) the dsRNA has a 2 nucleotide overhang at the 3′-end of the antisense strand; and
(g) phosphorothioate internucleotide linkage modifications, when present, only occur within a terminal region at one or both termini of the sense strand, one or both termini of the antisense strand, or one or both termini of both strands, wherein the terminal region is the last 5 nucleotides of a strand.

### Claim 22 (depends on 21)

The dsRNA of claim 21, having 3 nucleotides linked through phosphorothioate internucleotide linkages at each end of the antisense strand.

### Claim 23 (depends on 21)

The dsRNA of claim 21, wherein the first base pair within the duplex region from the 5′-end of the antisense strand is an A:U base pair.

### Claim 24 (depends on 21)

The dsRNA of claim 21, wherein the ligand is an asialoglycoprotein receptor (ASGPR) ligand, and the ASGPR ligand is one or more GalNAc derivatives attached through a bivalent or trivalent branched linker.

### Claim 25 (depends on 24)

The dsRNA of claim 24, wherein the ASGPR ligand is:

### Claim 26

A dsRNA comprising,
(a) a sense strand having:
(i) a length of 21 nucleotides;
(ii) an asialoglycoprotein receptor (ASGPR) ligand attached to the 3′-end, wherein said ASGPR ligand comprises three GalNAc derivatives attached through a trivalent branched linker;
(iii) 2′-O-Methyl (2′-OMe) modifications at positions 1 to 6, 8, and 12 to 21, and 2′-deoxy-2′-fluoro (2′-F) modifications at positions 7, and 9 to 11; counting from the 5′-end of the sense strand; and
(iv) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, and between nucleotide positions 2 and 3, counting from the 5′-end of the sense strand; and
(b) an antisense strand having:
(i) a length of 23 nucleotides;
(ii) 2′-OMe modifications at positions 1, 3 to 5, 7, 8, 10 to 13, 15, and 17 to 23, and 2′-F modifications at positions 2, 6, 9, 14, and 16, counting from the 5′-end of the antisense strand; and
(iii) phosphorothioate internucleotide linkages between nucleotide positions 1 and 2, between nucleotide positions 2 and 3, between nucleotide positions 21 and 22, and between nucleotide positions 22 and 23, counting from the 5′-end of the antisense strand;
wherein the dsRNA has a two-nucleotide overhang at the 3′-end of the antisense strand, and a blunt end at the 5′-end of the antisense strand.

### Claim 27 (depends on 26)

The dsRNA of claim 26, wherein the ASGPR ligand is:

### Claim 28 (depends on 27)

The dsRNA of claim 27, wherein the antisense strand is at least 90% complementary to a portion of the target mRNA.

### Claim 29 (depends on 27)

The dsRNA of claim 27, wherein the antisense strand is at least 95% complementary to a portion of the target mRNA.

### Claim 30 (depends on 29)

The dsRNA of claim 29, wherein the first base pair within the duplex region from the 5′-end of the antisense strand is an A:U base pair.
